Abstract
The UDP glucuronosyltransferase (UGT) content of cells and tissues is a major determinant of our response to those chemicals that are primarily eliminated by conjugation with glucuronic acid. There are marked interindividual differences in the content of UGTs in the liver and other organs. The mechanisms that lead to these differences are unknown but are most likely the result of differential UGT gene expression. Several transcription factors involved in the regulation of UGT genes have been identified. These include factors such as Hepatocyte Nuclear Factor 1, CAAT-Enhancer Binding Protein , Octamer transcription Factor 1 and Pbx2, which appear to control the constitutive levels of UGTs in tissues and organs. In addition, UGT gene expression is also modulated by hormones, drugs and other foreign chemicals through the action of proteins that bind and / or sense the presence of these chemicals. These proteins include the Ah receptor, members of the nuclear receptor superfamily, such as CAR and PXR and transcription factors that respond to stress.
Keywords: udp glucuronosyltransferase genes, ugt, hepatocyte nuclear factor, caat-enhancer binding protein, octamer transcription factor 1, nuclear receptor superfamily
Current Drug Metabolism
Title: Regulation of UDP Glucuronosyltransferase Genes
Volume: 4 Issue: 3
Author(s): P. I. Mackenzie, P. A. Gregory, D. A. Gardner-Stephen, R. H. Lewinsky, B. R. Jorgensen, T. Nishiyama, Wen Xie and A. Radominska-Pandya
Affiliation:
Keywords: udp glucuronosyltransferase genes, ugt, hepatocyte nuclear factor, caat-enhancer binding protein, octamer transcription factor 1, nuclear receptor superfamily
Abstract: The UDP glucuronosyltransferase (UGT) content of cells and tissues is a major determinant of our response to those chemicals that are primarily eliminated by conjugation with glucuronic acid. There are marked interindividual differences in the content of UGTs in the liver and other organs. The mechanisms that lead to these differences are unknown but are most likely the result of differential UGT gene expression. Several transcription factors involved in the regulation of UGT genes have been identified. These include factors such as Hepatocyte Nuclear Factor 1, CAAT-Enhancer Binding Protein , Octamer transcription Factor 1 and Pbx2, which appear to control the constitutive levels of UGTs in tissues and organs. In addition, UGT gene expression is also modulated by hormones, drugs and other foreign chemicals through the action of proteins that bind and / or sense the presence of these chemicals. These proteins include the Ah receptor, members of the nuclear receptor superfamily, such as CAR and PXR and transcription factors that respond to stress.
Export Options
About this article
Cite this article as:
Mackenzie I. P., Gregory A. P., Gardner-Stephen A. D., Lewinsky H. R., Jorgensen R. B., Nishiyama T., Xie Wen and Radominska-Pandya A., Regulation of UDP Glucuronosyltransferase Genes, Current Drug Metabolism 2003; 4 (3) . https://dx.doi.org/10.2174/1389200033489442
DOI https://dx.doi.org/10.2174/1389200033489442 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Drug Transporters in Chemotherapy Induced Peripheral Neurotoxicity:Current Knowledge and Clinical Implications
Current Medicinal Chemistry Relationships Between the Structural Properties of Flavonoids and their Inhibitory Activities Against Matrix Metallopeptidase 9
Letters in Drug Design & Discovery Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold
Anti-Cancer Agents in Medicinal Chemistry Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance
Anti-Cancer Agents in Medicinal Chemistry Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Evaluation of the Stability of Resveratrol Pluronic<sup>®</sup> Micelles Prepared by Solvent Casting and Simple Equilibrium Methods
Pharmaceutical Nanotechnology Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues
Recent Patents on Anti-Cancer Drug Discovery Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis
Current Drug Targets The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Current Pharmaceutical Design Parallel Solid-Phase Synthesis using a New Diethylsilylacetylenic Linker and Leading to Mestranol Derivatives with Potent Antiproliferative Activities on Multiple Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Effects of Surface Morphology Variation on the Degradation Rate of Poly(L-Lactic Acid) Membranes and the Behavior of Attached Cells
Micro and Nanosystems Vitamin D and Physical Performance in Athletes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)